CommercialBilling CodesMedium impact
08.00.51m, Enzyme Replacement for the Treatment of Gaucher's Disease
Independence Blue Cross·Hematology, Genetics, Pediatrics +2 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued policy 08.00.51m with a HCPCS code deletion effective 01/01/2026. Alglucerase (Ceredase®) injection code J0205 has been removed from the policy because the drug is no longer manufactured and has been withdrawn from market. Billing teams must immediately stop using this code and ensure claims are not submitted under this deleted code.
Action Required
By January 1, 2026: Billing team must remove HCPCS code J0205 (Injection, alglucerase, per 10 units) from all billing systems, EMR templates, and fee schedules. Audit any pending or in-process claims using J0205 and deny or refile as appropriate. Update billing software rules to prevent future submission of J0205. Verify no active patient orders or prescriptions remain for Ceredase® (alglucerase). Any claims submitted with J0205 after the effective date will be denied by Independence Blue Cross. Notify providers that Ceredase® is no longer available and covered enzyme replacement therapy options are limited to imiglucerase (J1786), taliglucerase alfa (J3060), or velaglucerase alfa (J3385).